Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 346

The DOI matches its Crossref record.

Eculizumab for Atypical Hemolytic–Uremic Syndrome

Open access
Nürnberger, Jens, Philipp, Thomas, Witzke, Oliver, Saez, Anabelle Opazo, Vester, Udo, Baba, Hideo Andreas, Kribben, Andreas, Zimmerhackl, Lothar Bernd, Janecke, Andreas R., Nagel, Mato, Kirschfink, Michael·2009·New England Journal of Medicine

Abstract

To the Editor: Atypical hemolytic–uremic syndrome is a disease of uncontrolled complement activation associated with a high mortality rate, and most cases progress to end-stage renal disease.1 About 50% of patients with this syndrome carry mutations in genes encoding complement proteins.2 Complement inhibition has been suggested for the treatment of atypical hemolytic–uremic syndrome,3 but currently no data on this treatment option are available. We report on a case of atypical hemolytic–uremic syndrome that was successfully treated with eculizumab, a humanized monoclonal antibody that blocks complement activity by cleavage of the complement protein C5, thereby preventing the generation of the inflammatory . . .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmc0808527

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 346

Metadata

Authors
Nürnberger, J., Philipp, T., Witzke, O., Saez, A. O., Vester, U., Baba, H. A., Kribben, A., Zimmerhackl, L. B., Janecke, A. R., Nagel, M., & Kirschfink, M.
Venue
New England Journal of Medicine
Published
2009-01-29
Volume
360
Issue
5
Pages
542-544
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2012630248
Cited by
346
References
0
FWCI
18.71
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Eculizumab for Atypical Hemolytic–Uremic Syndrome. https://app.cochat.ai/papers/10.1056/nejmc0808527
The paper
Nürnberger, J., Philipp, T., Witzke, O., Saez, A. O., Vester, U., Baba, H. A., Kribben, A., Zimmerhackl, L. B., Janecke, A. R., Nagel, M., & Kirschfink, M. (2009). Eculizumab for Atypical Hemolytic–Uremic Syndrome. New England Journal of Medicine. https://doi.org/10.1056/nejmc0808527

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.